Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma

Area of Science:

• Hematological Malignancies
• Cancer Drug Resistance
• Tumor Microenvironment Dynamics

Background:

• Multiple myeloma is an incurable blood cancer characterized by acquired drug resistance.
• De novo resistance arises from the tumor microenvironment (e.g., cell adhesion, cytokines, hypoxia).
• Acquired resistance is driven by clonal evolution (branching, linear, neutral).

Purpose of the Study:

• To review the role of anti-myeloma agents in modulating the microenvironment and clonal evolution.
• To summarize treatment strategies for overcoming drug resistance in multiple myeloma.
• To highlight the importance of initial treatment combinations.

Main Methods:

• Review of scientific literature on multiple myeloma pathogenesis and treatment.
• Analysis of mechanisms of de novo and acquired drug resistance.
• Evaluation of therapeutic agents targeting the myeloma microenvironment and clonal evolution.

Main Results:

• The tumor microenvironment and clonal evolution are key drivers of multiple myeloma drug resistance.
• Proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and ASCT improve prognosis by targeting the microenvironment.
• Branching evolution depends on the microenvironment, while linear/neutral evolution correlates with poor prognosis.

Conclusions:

• Effective treatment strategies must address both de novo and acquired drug resistance.
• Initial therapy incorporating proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and ASCT is vital.
• Understanding microenvironmental and evolutionary factors is critical for improving multiple myeloma outcomes.